Orforglipron
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 600
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Orforglipron Dose 1 | n/r | n/r | n/r | n/r |
| Orforglipron Dose 2 | n/r | n/r | n/r | n/r |
| Orforglipron Dose 3 | n/r | n/r | n/r | n/r |
| Orforglipron Dose 4 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Orforglipron Dose 1: endpoint not reported
- Orforglipron Dose 2: endpoint not reported
- Orforglipron Dose 3: endpoint not reported
- Orforglipron Dose 4: endpoint not reported
- Placebo: endpoint not reported